Chargement en cours...
Clinical Management of Adverse Events Associated with Lorlatinib
Lorlatinib is a novel, highly potent, brain‐penetrant, third‐generation ALK/ROS1 tyrosine kinase inhibitor (TKI), which has broad‐spectrum potency against most known resistance mutations that can develop during treatment with crizotinib and second‐generation ALK TKIs. The safety profile of lorlatini...
Enregistré dans:
| Publié dans: | Oncologist |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley & Sons, Inc.
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6693708/ https://ncbi.nlm.nih.gov/pubmed/30890623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0380 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|